Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyChlorothiazide
Identification
- Name
- Chlorothiazide
- Accession Number
- DB00880 (APRD00721)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
- Structure
Structure for DB00880 (Chlorothiazide)
- Synonyms
- 6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
- 6-chloro-7-Sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
- Chlorothiazid
- Chlorothiazide
- Chlorothiazidum
- Chlorthiazide
- Clorotiazida
- Mechlozid
- Uroflux
- Product Ingredients
Ingredient UNII CAS InChI Key Chlorothiazide Sodium SN86FG7N2K 7085-44-1 CPIWHAFLBZQYLQ-UHFFFAOYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Diuril Suspension 250 mg/5mL Oral Salix Pharmaceuticals 1962-02-15 Not applicable US 
Sodium Diuril Injection .5 mg/18mL Intravenous Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.) 1958-10-03 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Chlorothiazide Tablet 500 mg/1 Oral West Ward Pharmaceutical 2005-08-30 Not applicable US Chlorothiazide Injection, powder, lyophilized, for solution 500 mg/18mL Intravenous Fresenius Kabi 2009-10-21 Not applicable US Chlorothiazide Tablet 250 mg/1 Oral Golden State Medical Supply 2005-08-30 2017-10-26 US Chlorothiazide Tablet 500 mg/1 Oral Mylan Pharmaceuticals 1975-07-17 Not applicable US 
Chlorothiazide Tablet 250 mg/1 Oral West Ward Pharmaceutical 2005-08-30 Not applicable US Chlorothiazide Tablet 250 mg/1 Oral Avera Mc Kennan Hospital 2015-03-01 2018-05-23 US Chlorothiazide Tablet 250 mg/1 Oral Mylan Pharmaceuticals 1975-06-26 Not applicable US Chlorothiazide Tablet 500 mg/1 Oral Golden State Medical Supply 2005-08-30 2017-10-26 US 
Chlorothiazide Sodium Injection, powder, lyophilized, for solution 500 mg/18mL Intravenous Sagent Pharmaceuticals 2015-10-12 Not applicable US Chlorothiazide Sodium Injection 500 mg/1 Intravenous Akorn 2012-08-13 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Supres 150 Tab Chlorothiazide (150 mg) + Methyldopa (250 mg) Tablet Oral Merck Frosst Canada & Cie, Merck Frosst Canada & Co. 1972-12-31 2000-06-14 Canada 
Supres 250 Tab Chlorothiazide (250 mg) + Methyldopa (250 mg) Tablet Oral Merck Frosst Canada & Cie, Merck Frosst Canada & Co. 1972-12-31 2000-06-14 Canada - Categories
- Amides
- Antihypertensive Agents
- Benzothiadiazines
- Cardiovascular Agents
- Diuretics
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Hyperglycemia-Associated Agents
- Hypotensive Agents
- Membrane Transport Modulators
- Natriuretic Agents
- Sodium Chloride Symporter Inhibitors
- Sulfonamides
- Sulfones
- Sulfur Compounds
- Thiazides
- UNII
- 77W477J15H
- CAS number
- 58-94-6
- Weight
- Average: 295.723
Monoisotopic: 294.948824782 - Chemical Formula
- C7H6ClN3O4S2
- InChI Key
- JBMKAUGHUNFTOL-UHFFFAOYSA-N
- InChI
- InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
- IUPAC Name
- 6-chloro-1,1-dioxo-4H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
- SMILES
- NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1
Pharmacology
- Indication
Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
- Structured Indications
- Pharmacodynamics
Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
- Mechanism of action
As a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
Target Actions Organism ASolute carrier family 12 member 3 inhibitorHuman ACarbonic anhydrase 1 inhibitorHuman ACarbonic anhydrase 2 inhibitorHuman ACarbonic anhydrase 4 inhibitorHuman - Absorption
Rapidly absorbed following oral administration.
- Volume of distribution
- Not Available
- Protein binding
Approximately 40% bound to plasma proteins.
- Metabolism
Chlorothiazide is not metabolized but is eliminated rapidly by the kidney.
- Route of elimination
Chlorothiazide is not metabolized but is eliminated rapidly by the kidney. After oral doses, 10 to 15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
- Half life
45-120 minutes
- Clearance
- Not Available
- Toxicity
Oral, rat LD50: > 10 g/kg. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Chlorothiazide Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with (4R)-limonene. Investigational 16-Bromoepiandrosterone 16-Bromoepiandrosterone may increase the hypokalemic activities of Chlorothiazide. Investigational 19-norandrostenedione 19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide. Experimental, Illicit 1alpha-Hydroxyvitamin D5 The risk or severity of hyperkalemia can be increased when 1alpha-Hydroxyvitamin D5 is combined with Chlorothiazide. Investigational 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Chlorothiazide. Investigational 5-androstenedione 5-androstenedione may increase the hypokalemic activities of Chlorothiazide. Experimental, Illicit 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Chlorothiazide. Experimental Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Chlorothiazide. Approved, Investigational Acebutolol Chlorothiazide may increase the hypotensive activities of Acebutolol. Approved, Investigational Aceclofenac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Aceclofenac. Approved, Investigational Acemetacin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorothiazide. Approved, Investigational, Withdrawn Acetyldigitoxin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigitoxin. Approved Acetyldigoxin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigoxin. Experimental Acetylsalicylic acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acetylsalicylic acid. Approved, Vet Approved Aclidinium The serum concentration of Chlorothiazide can be increased when it is combined with Aclidinium. Approved Adapalene The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Adapalene. Approved AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Chlorothiazide. Experimental, Investigational Alaproclate Alaproclate may increase the hyponatremic activities of Chlorothiazide. Experimental Alclofenac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Alclofenac. Approved, Withdrawn Alclometasone Alclometasone may increase the hypokalemic activities of Chlorothiazide. Approved Alcuronium The serum concentration of Chlorothiazide can be increased when it is combined with Alcuronium. Experimental Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide. Approved Aldosterone Aldosterone may increase the hypokalemic activities of Chlorothiazide. Experimental, Investigational Alfacalcidol The risk or severity of hyperkalemia can be increased when Alfacalcidol is combined with Chlorothiazide. Approved, Nutraceutical Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorothiazide. Approved, Illicit Alfuzosin Alfuzosin may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Aliskiren Chlorothiazide may increase the hypotensive activities of Aliskiren. Approved, Investigational Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Chlorothiazide. Investigational Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Chlorothiazide. Approved Alminoprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Alminoprofen. Experimental Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorothiazide. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorothiazide. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Alphaprodine is combined with Chlorothiazide. Illicit Alprenolol Alprenolol may increase the hypotensive activities of Chlorothiazide. Approved, Withdrawn Ambrisentan Chlorothiazide may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amcinonide Amcinonide may increase the hypokalemic activities of Chlorothiazide. Approved Amifostine Chlorothiazide may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Chlorothiazide. Approved Amiodarone The risk or severity of adverse effects can be increased when Amiodarone is combined with Chlorothiazide. Approved, Investigational Amlodipine Amlodipine may increase the hypotensive activities of Chlorothiazide. Approved Amobarbital Amobarbital may increase the orthostatic hypotensive activities of Chlorothiazide. Approved, Illicit Amphetamine Amphetamine may increase the hypotensive activities of Chlorothiazide. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorothiazide. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amyl Nitrite. Approved Andrographolide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Andrographolide. Investigational Androstenedione Androstenedione may increase the hypokalemic activities of Chlorothiazide. Experimental, Illicit Anecortave Anecortave may increase the hypokalemic activities of Chlorothiazide. Investigational anecortave acetate anecortave acetate may increase the hypokalemic activities of Chlorothiazide. Investigational Anisodamine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Anisodamine. Investigational Anisotropine Methylbromide The serum concentration of Chlorothiazide can be increased when it is combined with Anisotropine Methylbromide. Approved Antipyrine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Antipyrine. Approved, Investigational Apocynin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Apocynin. Investigational Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorothiazide. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Apraclonidine. Approved Apremilast The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Apremilast. Approved, Investigational Arbutamine Arbutamine may increase the hypokalemic activities of Chlorothiazide. Approved Arformoterol Arformoterol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Chlorothiazide. Investigational Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Chlorothiazide. Approved, Investigational Atamestane Atamestane may increase the hypokalemic activities of Chlorothiazide. Investigational Atenolol Atenolol may increase the hypotensive activities of Chlorothiazide. Approved Atracurium The serum concentration of Chlorothiazide can be increased when it is combined with Atracurium. Approved, Experimental, Investigational Atracurium besylate The serum concentration of Chlorothiazide can be increased when it is combined with Atracurium besylate. Approved Atropine The serum concentration of Chlorothiazide can be increased when it is combined with Atropine. Approved, Vet Approved Avanafil Avanafil may increase the antihypertensive activities of Chlorothiazide. Approved Azapropazone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone. Withdrawn Azelastine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azelastine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Azilsartan medoxomil. Approved, Investigational Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Chlorothiazide. Investigational Balsalazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Balsalazide. Approved, Investigational Bambuterol Bambuterol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Barbexaclone Barbexaclone may increase the orthostatic hypotensive activities of Chlorothiazide. Experimental Barbital Barbital may increase the orthostatic hypotensive activities of Chlorothiazide. Illicit Barnidipine Chlorothiazide may increase the antihypertensive activities of Barnidipine. Approved Beclomethasone dipropionate Beclomethasone dipropionate may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Becocalcidiol The risk or severity of hyperkalemia can be increased when Becocalcidiol is combined with Chlorothiazide. Investigational Bempedoic acid The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Chlorothiazide. Investigational Benactyzine The serum concentration of Chlorothiazide can be increased when it is combined with Benactyzine. Withdrawn Benazepril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Benazepril. Approved, Investigational Bendazac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bendazac. Experimental Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Chlorothiazide. Approved Benmoxin Benmoxin may increase the hypotensive activities of Chlorothiazide. Withdrawn Benorilate The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benorilate. Experimental Benoxaprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benoxaprofen. Withdrawn Benzatropine The serum concentration of Chlorothiazide can be increased when it is combined with Benzatropine. Approved Benzydamine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benzydamine. Approved Bepridil Chlorothiazide may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betamethasone Betamethasone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Betaxolol Betaxolol may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Chlorothiazide. Approved Bevonium The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bevonium. Experimental Bezitramide The risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorothiazide. Experimental, Illicit, Withdrawn Bietaserpine Bietaserpine may increase the hypotensive activities of Chlorothiazide. Experimental Bimatoprost Chlorothiazide may increase the hypotensive activities of Bimatoprost. Approved, Investigational Biperiden The serum concentration of Chlorothiazide can be increased when it is combined with Biperiden. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Chlorothiazide. Approved Bornaprine The serum concentration of Chlorothiazide can be increased when it is combined with Bornaprine. Experimental Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Chlorothiazide. Approved, Investigational Bosentan Bosentan may increase the hypotensive activities of Chlorothiazide. Approved, Investigational BQ-123 Chlorothiazide may increase the hypotensive activities of BQ-123. Investigational Bretylium Chlorothiazide may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Chlorothiazide. Approved Brofaromine Brofaromine may increase the hypotensive activities of Chlorothiazide. Experimental Bromfenac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bromfenac. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorothiazide. Approved, Investigational Bucillamine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bucillamine. Investigational Budesonide Budesonide may increase the hypokalemic activities of Chlorothiazide. Approved Bufexamac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bufexamac. Approved, Experimental Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Chlorothiazide. Investigational, Withdrawn Bumadizone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bumadizone. Experimental Bumetanide The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorothiazide. Approved, Investigational Bupranolol Chlorothiazide may increase the hypotensive activities of Bupranolol. Approved Buprenorphine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide. Approved, Illicit, Investigational, Vet Approved Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorothiazide. Approved, Illicit, Vet Approved Butylscopolamine The serum concentration of Chlorothiazide can be increased when it is combined with Butylscopolamine. Approved, Investigational, Vet Approved Cadralazine Cadralazine may increase the hypotensive activities of Chlorothiazide. Experimental Cafedrine Chlorothiazide may increase the hypotensive activities of Cafedrine. Investigational Calcidiol The risk or severity of hyperkalemia can be increased when Calcidiol is combined with Chlorothiazide. Approved, Nutraceutical Calcipotriol The risk or severity of hyperkalemia can be increased when Calcipotriol is combined with Chlorothiazide. Approved Calcitriol The risk or severity of hyperkalemia can be increased when Calcitriol is combined with Chlorothiazide. Approved, Nutraceutical Calcium Acetate Chlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level. Approved, Investigational Calcium Carbonate Chlorothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level. Approved, Investigational Calcium Chloride Chlorothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level. Approved Calcium Citrate Chlorothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level. Approved Calcium glubionate Chlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level. Approved Calcium Gluceptate Chlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level. Approved Calcium gluconate Chlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level. Approved, Vet Approved Calcium lactate Chlorothiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level. Approved, Investigational, Vet Approved Calcium lactate gluconate Chlorothiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level. Experimental Calcium levulinate Chlorothiazide may decrease the excretion rate of Calcium levulinate which could result in a higher serum level. Approved, Experimental Calcium pangamate Chlorothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. Experimental Calcium Phosphate Chlorothiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level. Approved Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide. Approved Candesartan Chlorothiazide may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Chlorothiazide. Approved Candoxatril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Candoxatril. Experimental Captopril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Captopril. Approved Carbamazepine The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carbaspirin calcium. Experimental, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Chlorothiazide. Approved, Investigational Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Chlorothiazide. Experimental Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorothiazide. Illicit, Investigational, Vet Approved Caroxazone Caroxazone may increase the hypotensive activities of Chlorothiazide. Withdrawn Carprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Carteolol may increase the hypotensive activities of Chlorothiazide. Approved Carvedilol Chlorothiazide may increase the hypotensive activities of Carvedilol. Approved, Investigational Casein Chlorothiazide may decrease the excretion rate of Casein which could result in a higher serum level. Approved Castanospermine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Castanospermine. Experimental Celecoxib The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Celecoxib. Approved, Investigational Celiprolol Celiprolol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Chloroquine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Chloroquine. Approved, Investigational, Vet Approved Chlorphenoxamine The serum concentration of Chlorothiazide can be increased when it is combined with Chlorphenoxamine. Withdrawn Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlorothiazide. Approved, Investigational, Vet Approved Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Chlorthalidone Chlorthalidone may increase the hypotensive activities of Chlorothiazide. Approved Cholecalciferol The risk or severity of hyperkalemia can be increased when Cholecalciferol is combined with Chlorothiazide. Approved, Nutraceutical Cholestyramine Cholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Choline magnesium trisalicylate. Approved Ciclesonide Ciclesonide may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Cicletanine Chlorothiazide may increase the hypotensive activities of Cicletanine. Investigational Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorothiazide. Experimental Cilazapril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Chlorothiazide. Approved, Investigational Citalopram Citalopram may increase the hyponatremic activities of Chlorothiazide. Approved Clenbuterol Clenbuterol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational, Vet Approved Clevidipine The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine. Approved, Investigational Clobetasol Clobetasol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Clobetasol propionate Clobetasol propionate may increase the hypokalemic activities of Chlorothiazide. Approved Clobetasone Clobetasone may increase the hypokalemic activities of Chlorothiazide. Approved Clocortolone Clocortolone may increase the hypokalemic activities of Chlorothiazide. Approved Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Chlorothiazide. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Chlorothiazide. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Chlorothiazide. Approved Clonixin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Clonixin. Approved Cloranolol Chlorothiazide may increase the hypotensive activities of Cloranolol. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Chlorothiazide. Approved Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Chlorothiazide. Approved, Illicit Colesevelam Colesevelam can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Chlorothiazide. Approved, Investigational Cortexolone 17α-propionate Cortexolone 17α-propionate may increase the hypokalemic activities of Chlorothiazide. Investigational Corticosterone Corticosterone may increase the hypokalemic activities of Chlorothiazide. Experimental Cortisone acetate Cortisone acetate may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Cryptenamine Cryptenamine may increase the hypotensive activities of Chlorothiazide. Approved Curcumin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Curcumin. Approved, Investigational Cyclopenthiazide Chlorothiazide may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclopentolate The serum concentration of Chlorothiazide can be increased when it is combined with Cyclopentolate. Approved Cyclophosphamide The risk or severity of severe leukopenia can be increased when Chlorothiazide is combined with Cyclophosphamide. Approved, Investigational Cyclothiazide Cyclothiazide may increase the hypotensive activities of Chlorothiazide. Approved Cymarin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cymarin. Experimental Dapagliflozin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dapagliflozin. Approved Dapoxetine Dapoxetine may increase the hyponatremic activities of Chlorothiazide. Investigational Darifenacin The serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin. Approved, Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Deflazacort Deflazacort may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Delapril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Delapril. Experimental Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Chlorothiazide. Investigational Deserpidine Chlorothiazide may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Chlorothiazide. Approved Deslanoside The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Deslanoside. Approved Desloratadine The serum concentration of Chlorothiazide can be increased when it is combined with Desloratadine. Approved, Investigational Desonide Desonide may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Desoximetasone Desoximetasone may increase the hypokalemic activities of Chlorothiazide. Approved Desoxycorticosterone acetate Desoxycorticosterone acetate may increase the hypokalemic activities of Chlorothiazide. Approved Desoxycorticosterone Pivalate Desoxycorticosterone Pivalate may increase the hypokalemic activities of Chlorothiazide. Experimental, Vet Approved Desvenlafaxine Desvenlafaxine may increase the hyponatremic activities of Chlorothiazide. Approved, Investigational Dexamethasone Dexamethasone may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Dexamethasone isonicotinate may increase the hypokalemic activities of Chlorothiazide. Vet Approved Dexetimide The serum concentration of Chlorothiazide can be increased when it is combined with Dexetimide. Withdrawn Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chlorothiazide. Approved, Investigational Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorothiazide. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorothiazide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorothiazide. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Chlorothiazide. Approved, Investigational Diazoxide The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diazoxide. Approved Diclofenac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diclofenac. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diclofenamide. Approved, Investigational Dicyclomine The serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine. Approved Diethylnorspermine Chlorothiazide may increase the hypotensive activities of Diethylnorspermine. Investigational Difenpiramide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Difenpiramide. Experimental Diflorasone Diflorasone may increase the hypokalemic activities of Chlorothiazide. Approved Diflunisal The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diflunisal. Approved, Investigational Difluocortolone Difluocortolone may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational, Withdrawn Difluprednate Difluprednate may increase the hypokalemic activities of Chlorothiazide. Approved Digitoxin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin. Approved, Investigational Digoxin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin. Approved Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin Immune Fab (Ovine). Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorothiazide. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorothiazide. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorothiazide. Experimental, Illicit Dihydrotachysterol The risk or severity of hyperkalemia can be increased when Dihydrotachysterol is combined with Chlorothiazide. Approved Diltiazem Diltiazem may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab. Approved, Investigational Diphenhydramine The serum concentration of Chlorothiazide can be increased when it is combined with Diphenhydramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorothiazide. Approved, Illicit Dipivefrin Dipivefrin may increase the hypokalemic activities of Chlorothiazide. Approved Dipyridamole The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dipyridamole. Approved Dobutamine Dobutamine may increase the hypokalemic activities of Chlorothiazide. Approved Dofetilide Chlorothiazide may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dorzolamide Dorzolamide may increase the hypotensive activities of Chlorothiazide. Approved Doxazosin Doxazosin may increase the hypotensive activities of Chlorothiazide. Approved Doxercalciferol The risk or severity of hyperkalemia can be increased when Doxercalciferol is combined with Chlorothiazide. Approved Doxofylline Doxofylline may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational DPDPE The risk or severity of adverse effects can be increased when DPDPE is combined with Chlorothiazide. Experimental Droxicam The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Droxicam. Withdrawn Droxidopa Droxidopa may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Duloxetine Chlorothiazide may increase the orthostatic hypotensive activities of Duloxetine. Approved Duvelisib The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Duvelisib. Investigational E-6201 The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with E-6201. Investigational Efonidipine Chlorothiazide may increase the hypotensive activities of Efonidipine. Approved, Investigational Eldecalcitol The risk or severity of hyperkalemia can be increased when Eldecalcitol is combined with Chlorothiazide. Investigational Elocalcitol The risk or severity of hyperkalemia can be increased when Elocalcitol is combined with Chlorothiazide. Investigational Emepronium The serum concentration of Chlorothiazide can be increased when it is combined with Emepronium. Experimental Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorothiazide. Approved Enalapril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of hypotension can be increased when Chlorothiazide is combined with Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Chlorothiazide. Experimental Epanolol Chlorothiazide may increase the hypotensive activities of Epanolol. Experimental Ephedra Ephedra may increase the hypokalemic activities of Chlorothiazide. Approved, Nutraceutical, Withdrawn Epinephrine Epinephrine may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Epirizole The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Epirizole. Approved Eplerenone The risk or severity of adverse effects can be increased when Eplerenone is combined with Chlorothiazide. Approved Epoprostenol Chlorothiazide may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Eprosartan may increase the hypotensive activities of Chlorothiazide. Approved Equilenin Equilenin may increase the hypokalemic activities of Chlorothiazide. Experimental Equilin Equilin may increase the hypokalemic activities of Chlorothiazide. Approved Ergocalciferol The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Chlorothiazide. Approved, Nutraceutical Escitalopram Escitalopram may increase the hyponatremic activities of Chlorothiazide. Approved, Investigational Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Chlorothiazide. Approved Estrone Estrone may increase the hypokalemic activities of Chlorothiazide. Approved Estrone sulfate Estrone sulfate may increase the hypokalemic activities of Chlorothiazide. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid. Approved, Investigational Etafedrine Etafedrine may increase the hypokalemic activities of Chlorothiazide. Approved Etanautine The serum concentration of Chlorothiazide can be increased when it is combined with Etanautine. Experimental Etanercept The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etanercept. Approved, Investigational Ethanol Ethanol may increase the orthostatic hypotensive activities of Chlorothiazide. Approved Ethenzamide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ethenzamide. Experimental Ethopropazine The serum concentration of Chlorothiazide can be increased when it is combined with Ethopropazine. Approved Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorothiazide. Approved, Illicit Etodolac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etodolac. Approved, Investigational, Vet Approved Etofenamate The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etofenamate. Approved, Investigational Etoperidone Etoperidone may increase the hyponatremic activities of Chlorothiazide. Withdrawn Etoricoxib The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib. Approved, Investigational Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Chlorothiazide. Illicit, Vet Approved Etybenzatropine The serum concentration of Chlorothiazide can be increased when it is combined with Etybenzatropine. Experimental Evening primrose oil The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Evening primrose oil. Investigational, Nutraceutical Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Exisulind The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Exisulind. Investigational Felbinac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Felbinac. Experimental Felodipine Chlorothiazide may increase the hypotensive activities of Felodipine. Approved, Investigational Fenbufen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenbufen. Approved Fenoldopam Fenoldopam may increase the hypotensive activities of Chlorothiazide. Approved Fenoprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenoprofen. Approved Fenoterol Fenoterol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorothiazide. Approved, Illicit, Investigational, Vet Approved Fentiazac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fentiazac. Experimental Feprazone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Feprazone. Experimental Ferulic acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ferulic acid. Experimental Fesoterodine The serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine. Approved Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Chlorothiazide. Approved, Investigational Flavoxate The serum concentration of Chlorothiazide can be increased when it is combined with Flavoxate. Approved Floctafenine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Floctafenine. Approved, Withdrawn Fluasterone Fluasterone may increase the hypokalemic activities of Chlorothiazide. Investigational Fludrocortisone Fludrocortisone may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Flumethasone Flumethasone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Flunisolide Flunisolide may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Flunixin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flunixin. Vet Approved Flunoxaprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flunoxaprofen. Experimental Fluocinolone Acetonide Fluocinolone Acetonide may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational, Vet Approved Fluocinonide Fluocinonide may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Fluocortolone Fluocortolone may increase the hypokalemic activities of Chlorothiazide. Approved, Withdrawn Fluorometholone Fluorometholone may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Fluoxetine Fluoxetine may increase the hyponatremic activities of Chlorothiazide. Approved, Vet Approved Fluprednidene Fluprednidene may increase the hypokalemic activities of Chlorothiazide. Approved, Withdrawn Fluprednisolone Fluprednisolone may increase the hypokalemic activities of Chlorothiazide. Approved Flurandrenolide Flurandrenolide may increase the hypokalemic activities of Chlorothiazide. Approved Flurbiprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flurbiprofen. Approved, Investigational Fluticasone furoate Fluticasone furoate may increase the hypokalemic activities of Chlorothiazide. Approved Fluticasone propionate Fluticasone propionate may increase the hypokalemic activities of Chlorothiazide. Approved Fluvoxamine Fluvoxamine may increase the hyponatremic activities of Chlorothiazide. Approved, Investigational Formestane Formestane may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational, Withdrawn Formoterol Formoterol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Fosinopril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Fosinopril. Approved Furazolidone Furazolidone may increase the hypotensive activities of Chlorothiazide. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Furosemide is combined with Chlorothiazide. Approved, Vet Approved Gallamine The serum concentration of Chlorothiazide can be increased when it is combined with Gallamine. Experimental Gallamine Triethiodide The serum concentration of Chlorothiazide can be increased when it is combined with Gallamine Triethiodide. Approved Gitoformate The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Gitoformate. Experimental Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorothiazide. Investigational, Withdrawn Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Chlorothiazide. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide. Approved Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorothiazide. Approved, Investigational Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorothiazide. Approved Glycopyrronium The serum concentration of Chlorothiazide can be increased when it is combined with Glycopyrronium. Approved, Investigational, Vet Approved Guacetisal The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Guacetisal. Experimental Guanabenz Guanabenz may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Chlorothiazide. Approved Guanazodine Chlorothiazide may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Chlorothiazide may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Guanoclor Chlorothiazide may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Chlorothiazide may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Chlorothiazide may increase the hypotensive activities of Guanoxan. Experimental Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Chlorothiazide. Investigational Halcinonide Halcinonide may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational, Withdrawn Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Chlorothiazide. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Chlorothiazide. Experimental HE3286 HE3286 may increase the hypokalemic activities of Chlorothiazide. Investigational Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Chlorothiazide. Approved, Illicit, Investigational Hexamethonium Chlorothiazide may increase the hypotensive activities of Hexamethonium. Experimental Hexobarbital Hexobarbital may increase the orthostatic hypotensive activities of Chlorothiazide. Approved Higenamine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Higenamine. Investigational Homatropine The serum concentration of Chlorothiazide can be increased when it is combined with Homatropine. Approved Hydracarbazine Hydracarbazine may increase the hypotensive activities of Chlorothiazide. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Chlorothiazide. Approved Hydrochlorothiazide Chlorothiazide may increase the hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide. Approved, Illicit Hydrocortisone Hydrocortisone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide. Approved, Illicit Hyoscyamine The serum concentration of Chlorothiazide can be increased when it is combined with Hyoscyamine. Approved Ibuprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuprofen. Approved Ibuproxam The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuproxam. Withdrawn Icatibant The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Icatibant. Approved, Investigational Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Chlorothiazide. Approved, Investigational Imidapril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Imidapril. Investigational Imidazole salicylate The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Imidazole salicylate. Experimental Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Chlorothiazide. Approved Indacaterol Indacaterol may increase the hypokalemic activities of Chlorothiazide. Approved Indalpine Indalpine may increase the hyponatremic activities of Chlorothiazide. Investigational, Withdrawn Indapamide Indapamide may increase the hypotensive activities of Chlorothiazide. Approved Indenolol Chlorothiazide may increase the hypotensive activities of Indenolol. Withdrawn Indobufen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indobufen. Investigational Indomethacin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin. Approved, Investigational Indoprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indoprofen. Withdrawn Indoramin Indoramin may increase the hypotensive activities of Chlorothiazide. Withdrawn Inecalcitol The risk or severity of hyperkalemia can be increased when Inecalcitol is combined with Chlorothiazide. Experimental, Investigational Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorothiazide. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Chlorothiazide. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorothiazide. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Chlorothiazide. Approved Insulin Human The therapeutic efficacy of Insulin Human can be decreased when used in combination with Chlorothiazide. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorothiazide. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorothiazide. Approved Ipratropium bromide The serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide. Approved Iproclozide Iproclozide may increase the hypotensive activities of Chlorothiazide. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Chlorothiazide. Withdrawn Irbesartan Chlorothiazide may increase the hypotensive activities of Irbesartan. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Chlorothiazide. Approved Isoetarine Isoetarine may increase the hypokalemic activities of Chlorothiazide. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorothiazide. Approved, Vet Approved Isoprenaline Isoprenaline may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Mononitrate. Approved Isoxicam The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Isoxicam. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Istaroxime Istaroxime may increase the hypokalemic activities of Chlorothiazide. Investigational Ivabradine Chlorothiazide may increase the arrhythmogenic activities of Ivabradine. Approved Kebuzone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Kebuzone. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Chlorothiazide. Investigational Ketobemidone The risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorothiazide. Approved, Investigational Ketoprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Ketorolac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketorolac. Approved Labetalol Labetalol may increase the hypotensive activities of Chlorothiazide. Approved Lacidipine Chlorothiazide may increase the hypotensive activities of Lacidipine. Approved, Investigational Lanatoside C The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Lanatoside C. Experimental Latanoprost Latanoprost may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Leflunomide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Leflunomide. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chlorothiazide. Approved, Investigational Levodopa Chlorothiazide may increase the orthostatic hypotensive activities of Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorothiazide. Approved, Investigational Levomilnacipran Levomilnacipran may increase the hyponatremic activities of Chlorothiazide. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorothiazide. Approved Levosalbutamol Levosalbutamol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Chlorothiazide. Approved, Investigational Licorice Licorice may increase the hypokalemic activities of Chlorothiazide. Approved Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide. Approved Linsidomine Chlorothiazide may increase the hypotensive activities of Linsidomine. Experimental Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Chlorothiazide. Approved Lisinopril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Lisinopril. Approved, Investigational Lisofylline The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lisofylline. Investigational Lithium Chlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level. Approved Lofentanil The risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorothiazide. Illicit Lofexidine Chlorothiazide may increase the hypotensive activities of Lofexidine. Approved, Investigational Lonazolac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lonazolac. Experimental Lornoxicam The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam. Approved, Investigational Losartan Losartan may increase the hypotensive activities of Chlorothiazide. Approved Loteprednol Loteprednol may increase the hypokalemic activities of Chlorothiazide. Approved Loxoprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Loxoprofen. Approved, Investigational Lumiracoxib The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lumiracoxib. Approved, Investigational Macitentan Chlorothiazide may increase the hypotensive activities of Macitentan. Approved Magnesium salicylate The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate. Approved Manidipine Chlorothiazide may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Mannitol is combined with Chlorothiazide. Approved, Investigational Masoprocol The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Masoprocol. Approved, Investigational Maxacalcitol The risk or severity of hyperkalemia can be increased when Maxacalcitol is combined with Chlorothiazide. Approved, Investigational Mazaticol The serum concentration of Chlorothiazide can be increased when it is combined with Mazaticol. Experimental ME-609 ME-609 may increase the hypokalemic activities of Chlorothiazide. Investigational Mebanazine Mebanazine may increase the hypotensive activities of Chlorothiazide. Withdrawn Mecamylamine The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine. Approved, Investigational Meclofenamic acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Medrysone Medrysone may increase the hypokalemic activities of Chlorothiazide. Approved Mefenamic acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mefenamic acid. Approved Melengestrol Melengestrol may increase the hypokalemic activities of Chlorothiazide. Vet Approved Meloxicam The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam. Approved, Vet Approved Meptazinol The risk or severity of adverse effects can be increased when Meptazinol is combined with Chlorothiazide. Experimental Mesalazine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine. Approved Metamizole The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole. Approved, Investigational, Withdrawn Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Chlorothiazide. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorothiazide. Approved, Illicit Methantheline The serum concentration of Chlorothiazide can be increased when it is combined with Methantheline. Approved, Investigational Methazolamide The risk or severity of adverse effects can be increased when Methazolamide is combined with Chlorothiazide. Approved Methohexital Methohexital may increase the orthostatic hypotensive activities of Chlorothiazide. Approved Methoserpidine Chlorothiazide may increase the hypotensive activities of Methoserpidine. Experimental Methscopolamine The serum concentration of Chlorothiazide can be increased when it is combined with Methscopolamine. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide. Approved Methyldopa Chlorothiazide may increase the hypotensive activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Chlorothiazide. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide. Approved Methylprednisolone Methylprednisolone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Methylscopolamine bromide The serum concentration of Chlorothiazide can be increased when it is combined with Methylscopolamine bromide. Approved Metildigoxin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Metildigoxin. Experimental Metipranolol Chlorothiazide may increase the hypotensive activities of Metipranolol. Approved Metixene The serum concentration of Chlorothiazide can be increased when it is combined with Metixene. Approved Metolazone Metolazone may increase the hypotensive activities of Chlorothiazide. Approved Metoprolol Metoprolol may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Metyrosine Chlorothiazide may increase the hypotensive activities of Metyrosine. Approved Mibefradil Chlorothiazide may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorothiazide. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Chlorothiazide. Approved Milnacipran Milnacipran may increase the hyponatremic activities of Chlorothiazide. Approved, Investigational Minaprine Minaprine may increase the hypotensive activities of Chlorothiazide. Approved Minoxidil Minoxidil may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Chlorothiazide. Investigational Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Mizoribine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mizoribine. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Moexipril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Moexipril. Approved Mofebutazone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mofebutazone. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Mometasone Mometasone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Chlorothiazide. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Muzolimine Chlorothiazide may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolate mofetil. Approved, Investigational Mycophenolic acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid. Approved Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Chlorothiazide. Approved, Investigational Nabumetone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nabumetone. Approved Nadolol Chlorothiazide may increase the hypotensive activities of Nadolol. Approved Nafamostat The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nafamostat. Approved, Investigational Naftifine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naftifine. Approved Naftopidil Chlorothiazide may increase the hypotensive activities of Naftopidil. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorothiazide. Approved Naproxen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naproxen. Approved, Vet Approved Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Chlorothiazide. Approved, Investigational NCX 1022 NCX 1022 may increase the hypokalemic activities of Chlorothiazide. Investigational Nebivolol Chlorothiazide may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone Nefazodone may increase the hyponatremic activities of Chlorothiazide. Approved, Withdrawn Nepafenac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nepafenac. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nesiritide. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Chlorothiazide. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Nicomorphine The risk or severity of adverse effects can be increased when Nicomorphine is combined with Chlorothiazide. Experimental Nicorandil Nicorandil may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nifedipine. Approved Nifenazone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nifenazone. Experimental Niflumic Acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Niflumic Acid. Approved Niguldipine Chlorothiazide may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Chlorothiazide may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide. Approved, Investigational, Withdrawn Nimodipine Nimodipine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Chlorothiazide. Approved Nitrendipine Chlorothiazide may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Chlorothiazide. Approved Nitroaspirin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nitroaspirin. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Chlorothiazide. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Nitrous acid is combined with Chlorothiazide. Approved, Investigational Norepinephrine Norepinephrine may increase the hypokalemic activities of Chlorothiazide. Approved Normethadone The risk or severity of adverse effects can be increased when Normethadone is combined with Chlorothiazide. Approved, Illicit Obinutuzumab Chlorothiazide may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Chlorothiazide. Withdrawn Oleandrin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Oleandrin. Experimental, Investigational Oleoyl-estrone Oleoyl-estrone may increase the hypokalemic activities of Chlorothiazide. Investigational Olmesartan Olmesartan may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Olodaterol Olodaterol may increase the hypokalemic activities of Chlorothiazide. Approved Olopatadine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine. Approved Olsalazine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine. Approved Omapatrilat The risk or severity of hypotension can be increased when Chlorothiazide is combined with Omapatrilat. Investigational Opium The risk or severity of adverse effects can be increased when Opium is combined with Chlorothiazide. Approved, Illicit Orciprenaline Orciprenaline may increase the hypokalemic activities of Chlorothiazide. Approved Orgotein The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Orgotein. Vet Approved Orphenadrine The serum concentration of Chlorothiazide can be increased when it is combined with Orphenadrine. Approved Otilonium The serum concentration of Chlorothiazide can be increased when it is combined with Otilonium. Experimental, Investigational Ouabain The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ouabain. Approved Oxaprozin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin. Approved Oxcarbazepine The risk or severity of hyponatremia can be increased when Chlorothiazide is combined with Oxcarbazepine. Approved Oxitropium The serum concentration of Chlorothiazide can be increased when it is combined with Oxitropium. Investigational Oxprenolol Chlorothiazide may increase the hypotensive activities of Oxprenolol. Approved Oxybutynin The serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorothiazide. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorothiazide. Approved, Investigational, Vet Approved Oxyphenbutazone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone. Approved, Withdrawn Oxyphenonium The serum concentration of Chlorothiazide can be increased when it is combined with Oxyphenonium. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorothiazide. Approved, Vet Approved Pancuronium The serum concentration of Chlorothiazide can be increased when it is combined with Pancuronium. Approved Papaverine The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine. Approved, Investigational Paramethasone Paramethasone may increase the hypokalemic activities of Chlorothiazide. Approved Parecoxib The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parecoxib. Approved Pargyline Pargyline may increase the hypotensive activities of Chlorothiazide. Approved Paricalcitol The risk or severity of hyperkalemia can be increased when Paricalcitol is combined with Chlorothiazide. Approved, Investigational Paroxetine Paroxetine may increase the hyponatremic activities of Chlorothiazide. Approved, Investigational Parthenolide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parthenolide. Approved, Investigational Penbutolol Chlorothiazide may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide. Approved, Vet Approved Pentobarbital Pentobarbital may increase the orthostatic hypotensive activities of Chlorothiazide. Approved, Investigational, Vet Approved Pentolinium The serum concentration of Chlorothiazide can be increased when it is combined with Pentolinium. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Perindopril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Perindopril. Approved Peruvoside The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Peruvoside. Experimental Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Chlorothiazide. Approved Phenazocine The risk or severity of adverse effects can be increased when Phenazocine is combined with Chlorothiazide. Experimental Phenelzine Phenelzine may increase the hypotensive activities of Chlorothiazide. Approved Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Chlorothiazide. Approved, Investigational, Withdrawn Phenglutarimide The serum concentration of Chlorothiazide can be increased when it is combined with Phenglutarimide. Experimental Pheniprazine Pheniprazine may increase the hypotensive activities of Chlorothiazide. Withdrawn Phenobarbital Phenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Phenoperidine is combined with Chlorothiazide. Experimental Phenoxybenzamine Chlorothiazide may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Chlorothiazide. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Chlorothiazide. Approved Phenylbutazone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Phenylbutazone. Approved, Vet Approved Phenylpropanolamine Phenylpropanolamine may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved, Withdrawn Pimecrolimus The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pimecrolimus. Approved, Investigational Pinacidil Pinacidil may increase the hypotensive activities of Chlorothiazide. Approved Pindolol Chlorothiazide may increase the hypotensive activities of Pindolol. Approved, Investigational Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorothiazide. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorothiazide. Approved, Investigational Pipecuronium The serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium. Approved Pirbuterol Pirbuterol may increase the hypokalemic activities of Chlorothiazide. Approved Pirenzepine The serum concentration of Chlorothiazide can be increased when it is combined with Pirenzepine. Approved Pirfenidone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirfenidone. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Piritramide is combined with Chlorothiazide. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Chlorothiazide. Approved Piroxicam The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam. Approved, Investigational Pirprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirprofen. Experimental Pivhydrazine Pivhydrazine may increase the hypotensive activities of Chlorothiazide. Withdrawn Platelet Activating Factor Chlorothiazide may increase the hypotensive activities of Platelet Activating Factor. Experimental Polythiazide Chlorothiazide may increase the hypotensive activities of Polythiazide. Approved Pramipexole The risk or severity of adverse effects can be increased when Pramipexole is combined with Chlorothiazide. Approved, Investigational Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Pranoprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pranoprofen. Experimental, Investigational Prasterone Prasterone may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational, Nutraceutical Prasterone sulfate Prasterone sulfate may increase the hypokalemic activities of Chlorothiazide. Investigational Prazosin Prazosin may increase the hypotensive activities of Chlorothiazide. Approved Prednicarbate Prednicarbate may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Prednisolone Prednisolone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Prednisone Prednisone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Pregnenolone Pregnenolone may increase the hypokalemic activities of Chlorothiazide. Approved, Experimental, Investigational Primidone Primidone may increase the orthostatic hypotensive activities of Chlorothiazide. Approved, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Procaterol Procaterol may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Procyclidine The serum concentration of Chlorothiazide can be increased when it is combined with Procyclidine. Approved Proglumetacin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Proglumetacin. Experimental Propacetamol The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Propacetamol. Approved, Investigational Propantheline The serum concentration of Chlorothiazide can be increased when it is combined with Propantheline. Approved Propiverine The serum concentration of Chlorothiazide can be increased when it is combined with Propiverine. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Chlorothiazide. Approved, Investigational, Vet Approved Propranolol Propranolol may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Propyphenazone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Propyphenazone. Experimental Proquazone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Proquazone. Experimental Proscillaridin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Proscillaridin. Experimental Protokylol Protokylol may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved PTC299 The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with PTC299. Investigational Quetiapine The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine. Approved Quinapril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Quinapril. Approved, Investigational Quinidine The serum concentration of Chlorothiazide can be increased when it is combined with Quinidine. Approved, Investigational Quinine Quinine may increase the hypotensive activities of Chlorothiazide. Approved Racepinephrine Racepinephrine may increase the hypokalemic activities of Chlorothiazide. Approved Ramipril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Ramipril. Approved Rasagiline Rasagiline may increase the hypotensive activities of Chlorothiazide. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorothiazide. Approved Remikiren Remikiren may increase the hypotensive activities of Chlorothiazide. Approved Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Rescinnamine The risk or severity of hypotension can be increased when Chlorothiazide is combined with Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Resveratrol The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol. Approved, Experimental, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Rimexolone Rimexolone may increase the hypokalemic activities of Chlorothiazide. Approved Riociguat Chlorothiazide may increase the hypotensive activities of Riociguat. Approved Risperidone Chlorothiazide may increase the hypotensive activities of Risperidone. Approved, Investigational Ritodrine Ritodrine may increase the hypokalemic activities of Chlorothiazide. Approved, Investigational Rituximab Chlorothiazide may increase the hypotensive activities of Rituximab. Approved Rofecoxib The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Rofecoxib. Approved, Investigational, Withdrawn Ropinirole The risk or severity of adverse effects can be increased when Ropinirole is combined with Chlorothiazide. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorothiazide. Approved Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorothiazide. Approved, Investigational Rotigotine The risk or severity of adverse effects can be increased when Rotigotine is combined with Chlorothiazide. Approved Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Chlorothiazide. Approved Safrazine Safrazine may increase the hypotensive activities of Chlorothiazide. Withdrawn Salbutamol Salbutamol may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Salicylamide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide. Approved Salicylic acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylic acid. Approved, Investigational, Vet Approved Salmeterol Salmeterol may increase the hypokalemic activities of Chlorothiazide. Approved Salsalate The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salsalate. Approved Saprisartan Chlorothiazide may increase the hypotensive activities of Saprisartan. Experimental Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Chlorothiazide. Approved Scopolamine The serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine. Approved, Investigational Secobarbital Secobarbital may increase the orthostatic hypotensive activities of Chlorothiazide. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Chlorothiazide. Approved, Investigational, Vet Approved Selexipag Chlorothiazide may increase the hypotensive activities of Selexipag. Approved Semapimod The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Semapimod. Investigational Seocalcitol The risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Chlorothiazide. Experimental, Investigational Seratrodast The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Seratrodast. Approved Serrapeptase The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Serrapeptase. Investigational Sertraline Sertraline may increase the hyponatremic activities of Chlorothiazide. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorothiazide. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Chlorothiazide. Approved, Investigational Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorothiazide. Approved, Investigational Sitaxentan Chlorothiazide may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium phosphate Chlorothiazide may increase the nephrotoxic activities of Sodium phosphate. Approved Solifenacin The serum concentration of Chlorothiazide can be increased when it is combined with Solifenacin. Approved Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Chlorothiazide. Investigational Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide. Approved Spirapril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Spironolactone is combined with Chlorothiazide. Approved SRT501 The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with SRT501. Investigational Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorothiazide. Approved, Investigational Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide. Approved, Investigational Sulfasalazine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulfasalazine. Approved Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride. Approved, Investigational Suprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen. Approved, Withdrawn Suxibuzone The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suxibuzone. Experimental Tacalcitol The risk or severity of hyperkalemia can be increased when Tacalcitol is combined with Chlorothiazide. Experimental, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Chlorothiazide. Approved, Investigational Talinolol Chlorothiazide may increase the hypotensive activities of Talinolol. Investigational Tamsulosin The risk or severity of adverse effects can be increased when Tamsulosin is combined with Chlorothiazide. Approved, Investigational Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorothiazide. Approved Tarenflurbil The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tarenflurbil. Investigational Telmisartan Chlorothiazide may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Temocapril. Experimental, Investigational Tenidap The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenidap. Experimental Tenoxicam The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenoxicam. Approved Tepoxalin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tepoxalin. Vet Approved Terazosin The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Terazosin. Approved Terbutaline Terbutaline may increase the hypokalemic activities of Chlorothiazide. Approved Teriflunomide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Teriflunomide. Approved Terlipressin Chlorothiazide may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Chlorothiazide may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorothiazide. Approved, Investigational, Withdrawn Theodrenaline Chlorothiazide may increase the hypotensive activities of Theodrenaline. Investigational Thiamylal Thiamylal may increase the orthostatic hypotensive activities of Chlorothiazide. Approved, Vet Approved Thiopental Thiopental may increase the orthostatic hypotensive activities of Chlorothiazide. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorothiazide. Approved, Withdrawn Tiaprofenic acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tiaprofenic acid. Approved Tibolone Chlorothiazide may increase the hypotensive activities of Tibolone. Approved, Investigational Ticrynafen Chlorothiazide may increase the hypotensive activities of Ticrynafen. Withdrawn Tilidine The risk or severity of adverse effects can be increased when Tilidine is combined with Chlorothiazide. Experimental Timolol Timolol may increase the hypotensive activities of Chlorothiazide. Approved Tinoridine The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tinoridine. Investigational Tiotropium The serum concentration of Chlorothiazide can be increased when it is combined with Tiotropium. Approved Tixocortol Tixocortol may increase the hypokalemic activities of Chlorothiazide. Approved, Withdrawn Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Tolazoline Tolazoline may increase the hypotensive activities of Chlorothiazide. Approved, Vet Approved Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorothiazide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorothiazide. Approved, Withdrawn Tolfenamic Acid The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolfenamic Acid. Approved, Investigational Tolmetin The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolmetin. Approved Tolonidine Chlorothiazide may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Chlorothiazide. Approved Tolterodine The serum concentration of Chlorothiazide can be increased when it is combined with Tolterodine. Approved, Investigational Torasemide Torasemide may increase the hypotensive activities of Chlorothiazide. Approved Toremifene Chlorothiazide may increase the hypercalcemic activities of Toremifene. Approved, Investigational Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Chlorothiazide. Approved, Investigational Trandolapril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Trandolapril. Approved Tranilast The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tranilast. Approved, Investigational Tranylcypromine Tranylcypromine may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Chlorothiazide. Approved Treprostinil Treprostinil may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Chlorothiazide. Approved, Investigational, Nutraceutical Triamcinolone Triamcinolone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Triamterene The risk or severity of adverse effects can be increased when Triamterene is combined with Chlorothiazide. Approved Tribenoside The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tribenoside. Experimental Trichlormethiazide Chlorothiazide may increase the hypotensive activities of Trichlormethiazide. Approved, Vet Approved Trihexyphenidyl The serum concentration of Chlorothiazide can be increased when it is combined with Trihexyphenidyl. Approved Trimazosin Trimazosin may increase the hypotensive activities of Chlorothiazide. Experimental Trimethaphan The serum concentration of Chlorothiazide can be increased when it is combined with Trimethaphan. Approved, Investigational Triptolide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Triptolide. Investigational Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Chlorothiazide. Investigational, Withdrawn Tropatepine The serum concentration of Chlorothiazide can be increased when it is combined with Tropatepine. Experimental Tropicamide The serum concentration of Chlorothiazide can be increased when it is combined with Tropicamide. Approved, Investigational Trospium The serum concentration of Chlorothiazide can be increased when it is combined with Trospium. Approved Tubocurarine The serum concentration of Chlorothiazide can be increased when it is combined with Tubocurarine. Approved Udenafil Udenafil may increase the antihypertensive activities of Chlorothiazide. Approved, Investigational Ulobetasol Ulobetasol may increase the hypokalemic activities of Chlorothiazide. Approved Umeclidinium The serum concentration of Chlorothiazide can be increased when it is combined with Umeclidinium. Approved Unoprostone Chlorothiazide may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Chlorothiazide. Investigational Valdecoxib The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Valdecoxib. Approved, Investigational, Withdrawn Valsartan Valsartan may increase the hypotensive activities of Chlorothiazide. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Chlorothiazide. Approved Vecuronium The serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium. Approved Venlafaxine Venlafaxine may increase the hyponatremic activities of Chlorothiazide. Approved Verapamil The risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide. Approved Vilanterol Vilanterol may increase the hypokalemic activities of Chlorothiazide. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorothiazide. Approved, Investigational Vincamine Chlorothiazide may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Chlorothiazide may increase the hypotensive activities of Vinpocetine. Investigational Vitamin D The risk or severity of hyperkalemia can be increased when Vitamin D is combined with Chlorothiazide. Approved, Nutraceutical, Vet Approved Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Chlorothiazide. Approved, Investigational Xipamide Chlorothiazide may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Chlorothiazide may increase the hypotensive activities of Xylometazoline. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Chlorothiazide. Approved, Investigational, Vet Approved Zaltoprofen The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zaltoprofen. Approved, Investigational Zileuton The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zileuton. Approved, Investigational, Withdrawn Zimelidine Zimelidine may increase the hyponatremic activities of Chlorothiazide. Withdrawn Zofenopril The risk or severity of hypotension can be increased when Chlorothiazide is combined with Zofenopril. Experimental Zomepirac The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zomepirac. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
Eugene S. Barabas, "Water soluble complex of a poly (vinyl lactam) and chlorothiazide and process for producing same." U.S. Patent US4713238, issued December, 1985.
US4713238- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015018
- KEGG Drug
- D00519
- KEGG Compound
- C07461
- PubChem Compound
- 2720
- PubChem Substance
- 46507032
- ChemSpider
- 2619
- BindingDB
- 39351
- ChEBI
- 3640
- ChEMBL
- CHEMBL842
- Therapeutic Targets Database
- DAP000605
- PharmGKB
- PA448953
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Chlorothiazide
- ATC Codes
- C03AB04 — Chlorothiazide and potassium
- C03AB — Thiazides and potassium in combination
- C03A — LOW-CEILING DIURETICS, THIAZIDES
- C03 — DIURETICS
- C — CARDIOVASCULAR SYSTEM
- C03AA — Thiazides, plain
- C03A — LOW-CEILING DIURETICS, THIAZIDES
- C03 — DIURETICS
- C — CARDIOVASCULAR SYSTEM
- C03AH — Thiazides, combinations with psycholeptics and/or analgesics
- C03A — LOW-CEILING DIURETICS, THIAZIDES
- C03 — DIURETICS
- C — CARDIOVASCULAR SYSTEM
- MSDS
- Download (72.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Prevention Cardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension) / Vascular Diseases 1 4 Enrolling by Invitation Treatment Heart Failure, Unspecified 1 Not Available Completed Screening Diabetes Insipidus, Nephrogenic 1 Not Available Recruiting Diagnostic Heart Failure, Unspecified 1
Pharmacoeconomics
- Manufacturers
- Salix pharmaceuticals inc
- Abc holding corp
- Lederle laboratories div american cyanamid co
- Mylan pharmaceuticals inc
- Sandoz inc
- Watson laboratories inc
- West ward pharmaceutical corp
- Lundbeck inc
- App pharmaceuticals llc
- Packagers
- APP Pharmaceuticals
- Ben Venue Laboratories Inc.
- Endo Pharmaceuticals Inc.
- Lundbeck Inc.
- Major Pharmaceuticals
- Merck & Co.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- PD-Rx Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Salix Pharmaceuticals
- Sandhills Packaging Inc.
- UDL Laboratories
- Watson Pharmaceuticals
- West-Ward Pharmaceuticals
- Dosage forms
Form Route Strength Tablet Oral 250 mg/1 Tablet Oral 500 mg/1 Injection Intravenous 500 mg/1 Injection, powder, lyophilized, for solution Intravenous 500 mg/18mL Suspension Oral 250 mg/5mL Injection Intravenous .5 mg/18mL Tablet Oral - Prices
Unit description Cost Unit Diuril sodium 500 mg vial 519.62USD vial Chlorothiazide sod 500 mg vial 357.24USD vial Microzide 12.5 mg capsule 0.95USD capsule Aldoclor 250-250 mg tablet 0.67USD tablet Chlorothiazide 500 mg tablet 0.36USD tablet Chlorothiazide 250 mg tablet 0.28USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 342.5-343 Novello, F.C.; US. Patent 2,809,194; October 8,1957; assigned to Merck & Co.,Inc. Hinkley, D.F.; US. Patent 2,937,169; May 17,1960; assigned to Merck & Co., Inc. water solubility 266 mg/L (at 30 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -0.24 HANSCH,C ET AL. (1995) logS -3.05 ADME Research, USCD Caco2 permeability -6.72 ADME Research, USCD pKa 6.85 MERCK INDEX (1996) - Predicted Properties
Property Value Source Water Solubility 0.398 mg/mL ALOGPS logP 0.41 ALOGPS logP -0.44 ChemAxon logS -2.9 ALOGPS pKa (Strongest Acidic) 9.1 ChemAxon pKa (Strongest Basic) 1.15 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 118.69 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 62.51 m3·mol-1 ChemAxon Polarizability 24.55 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9119 Blood Brain Barrier - 0.9506 Caco-2 permeable - 0.7368 P-glycoprotein substrate Non-substrate 0.706 P-glycoprotein inhibitor I Non-inhibitor 0.8482 P-glycoprotein inhibitor II Non-inhibitor 0.8381 Renal organic cation transporter Non-inhibitor 0.8177 CYP450 2C9 substrate Non-substrate 0.755 CYP450 2D6 substrate Non-substrate 0.8379 CYP450 3A4 substrate Non-substrate 0.6308 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.923 CYP450 2C19 inhibitor Non-inhibitor 0.9382 CYP450 3A4 inhibitor Non-inhibitor 0.8901 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8658 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.7792 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 1.5023 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9654 hERG inhibition (predictor II) Non-inhibitor 0.9352
Spectra
- Mass Spec (NIST)
- Download (10.1 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Thiadiazines
- Sub Class
- Benzothiadiazines
- Direct Parent
- 1,2,4-benzothiadiazine-1,1-dioxides
- Alternative Parents
- Organosulfonamides / Benzenoids / Aryl chlorides / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Formamidines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic oxides show 1 more
- Substituents
- 1,2,4-benzothiadiazine-1,1-dioxide / Aryl chloride / Aryl halide / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl / Aminosulfonyl compound / Propargyl-type 1,3-dipolar organic compound show 14 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- benzothiadiazine (CHEBI:3640)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transporter activity
- Specific Function
- Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
- Gene Name
- SLC12A3
- Uniprot ID
- P55017
- Uniprot Name
- Solute carrier family 12 member 3
- Molecular Weight
- 113138.04 Da
References
- Thakker RV: Molecular pathology of renal chloride channels in Dent's disease and Bartter's syndrome. Exp Nephrol. 2000 Nov-Dec;8(6):351-60. [PubMed:11014932]
- Schmidt H, Kabesch M, Schwarz HP, Kiess W: Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome. Horm Metab Res. 2001 Jun;33(6):354-7. [PubMed:11456284]
- Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP: Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):680-4. Epub 2003 Jan 6. [PubMed:12515852]
- Maki N, Komatsuda A, Wakui H, Ohtani H, Kigawa A, Aiba N, Hamai K, Motegi M, Yamaguchi A, Imai H, Sawada K: Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome. Nephrol Dial Transplant. 2004 Jul;19(7):1761-6. Epub 2004 Apr 6. [PubMed:15069170]
- Reinalter SC, Jeck N, Peters M, Seyberth HW: Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand. 2004 Aug;181(4):513-21. [PubMed:15283765]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
- Gene Name
- CA1
- Uniprot ID
- P00915
- Uniprot Name
- Carbonic anhydrase 1
- Molecular Weight
- 28870.0 Da
References
- Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865]
- Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
- Gene Name
- CA2
- Uniprot ID
- P00918
- Uniprot Name
- Carbonic anhydrase 2
- Molecular Weight
- 29245.895 Da
References
- Weiner ID, Verlander JW: Renal and hepatic expression of the ammonium transporter proteins, Rh B Glycoprotein and Rh C Glycoprotein. Acta Physiol Scand. 2003 Dec;179(4):331-8. [PubMed:14656370]
- Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127]
- Verlander JW, Miller RT, Frank AE, Royaux IE, Kim YH, Weiner ID: Localization of the ammonium transporter proteins RhBG and RhCG in mouse kidney. Am J Physiol Renal Physiol. 2003 Feb;284(2):F323-37. Epub 2002 Oct 8. [PubMed:12388412]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
- Gene Name
- CA4
- Uniprot ID
- P22748
- Uniprot Name
- Carbonic anhydrase 4
- Molecular Weight
- 35032.075 Da
References
- Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865]
- Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]
Drug created on June 13, 2005 07:24 / Updated on May 02, 2018 01:22